Sugi Predict

Sugi Predict / Compounds / SCHEMBL950792

SCHEMBL950792

SCHEMBL950792

C[C@@]12CCC[C@H]1[C@@H]1CCC3=CC(=O)CC[C@]3(C)[C@H]1CC2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 8/20 0.69
▸ SHBG P04278 6/20 0.69
▸ HSD17B10 Q99714 6/20 0.69
▸ SMN1; SMN2 Q16637 6/20 0.69
▸ LMNA P02545 5/20 0.69
▸ ALDH1A1 P00352 5/20 0.69
▸ SERPINA6 P08185 4/20 0.69
▸ SNCA P37840 4/20 0.69
▸ MAPK1 P28482 4/20 0.69
▸ TSHR P16473 4/20 0.69
▸ BLM P54132 3/20 0.69
▸ PMP22 Q01453 3/20 0.69
▸ NPSR1 Q6W5P4 3/20 0.69
▸ HSD17B3 P37058 2/20 0.69
▸ NR3C1 P04150 5/20 0.63
▸ PGR P06401 5/20 0.63
▸ ADRA1A P35348 1/20 0.63
▸ HTR2B P41595 1/20 0.63
▸ CYP3A4 P08684 4/20 0.62
▸ AR P10275 4/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14532645 1.00 CYP19A1 (0.69) CYP19A1SHBGHSD17B10SMN1; SMN2LMNA
SCHEMBL15380944 1.00 CYP19A1 (0.69) CYP19A1SHBGHSD17B10SMN1; SMN2LMNA
SCHEMBL18646434 1.00 CYP19A1 (0.69) CYP19A1SHBGHSD17B10SMN1; SMN2LMNA
SCHEMBL11860013 1.00 CYP19A1 (0.69) CYP19A1SHBGHSD17B10SMN1; SMN2LMNA
SCHEMBL950793 1.00 CYP19A1 (0.69) CYP19A1SHBGHSD17B10SMN1; SMN2LMNA
SCHEMBL13973080 1.00 CYP19A1 (0.69) CYP19A1SHBGHSD17B10SMN1; SMN2LMNA
SCHEMBL14455585 1.00 CYP19A1 (0.69) CYP19A1SHBGHSD17B10SMN1; SMN2LMNA
Androstenedione SCHEMBL21114424 0.87 CYP19A1 (0.71) CYP19A1SHBGHSD17B10SMN1; SMN2LMNA
SCHEMBL9157360 0.84 SHBG (0.66) CYP19A1SHBGHSD17B10SMN1; SMN2LMNA
SCHEMBL5925784 0.84 CYP19A1 (0.57) CYP19A1SHBGHSD17B10SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 444 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119930732-A Testosterone spiro compound and nano preparation, preparation method and application thereof 绍兴文理学院 2025-05-06 — — CN claimed
CN-116574702-A Hydroxylase capable of efficiently hydroxylating 9 alpha position of 4-androstene-3-ketone series compound and application thereof 上海交通大学 2023-08-11 — — CN claimed
WO-2022204827-A1 APPLICATION OF HALCINONIDE AND DERIVATIVES THEREOF FOR PREPARING DRUG TREATING AND/OR PREVENTING CEREBROVASCULAR DISEASE 兰州大学 2022-10-06 — — WO claimed
CN-114702543-A Clascoterone derivative or pharmaceutically acceptable salt thereof, and preparation method and application thereof 中国药科大学 2022-07-05 — — CN claimed
US-20220193095-A9 PHARMACEUTICAL COMPOSITIONS Shenzhen Pharmacin Co., Ltd. (CN) 2022-06-23 — — US claimed
EP-3914234-A1 PHARMACEUTICAL COMPOSITIONS Shenzhen Pharmacin Co., Ltd. (CN) 2021-12-01 — — EP claimed
CN-113473974-A Pharmaceutical composition 深圳市药欣生物科技有限公司 2021-10-01 — — CN claimed
CN-113069460-A Application of halcinonide and derivatives thereof in preparation of drugs for treating and/or preventing cerebrovascular diseases 兰州大学 2021-07-06 — — CN claimed
US-20200237784-A1 PHARMACEUTICAL COMPOSITIONS SHENZHEN PHARMACIN CO LTD (CN) 2020-07-30 — — US claimed
WO-2020151633-A1 PHARMACEUTICAL COMPOSITIONS Shenzhen Pharmacin Co., Ltd. (CN) 2020-07-30 — — WO claimed
JP-2742331-B2 — — 1998-04-22 — — JP claimed
WO-1998003207-A1 STEROIDS AS NEUROCHEMICAL STIMULATORS OF THE VNO TO ALLEVIATE SYMPTOMS OF PMS AND ANXIETY PHERIN PHARMACEUTICALS, INC. (US) 1998-01-29 — — WO claimed
WO-1997036596-A9 STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH — 1997-12-04 — — WO claimed
WO-1997036596-A1 STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN BLOOD LEVELS OF LH OR FSH PHERIN PHARMACEUTICALS, INC. (US) 1997-10-09 — — WO claimed
EP-0711169-A1 ANDROSTANE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS PHERIN CORPORATION (US) 1996-05-15 — — EP claimed
EP-0633893-A1 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT BRITISH TECHNOLOGY GROUP LTD (GB) 1995-01-18 — — EP claimed
WO-1994028904-A1 ANDROSTANE STEROIDS AS NEUROCHEMICAL INITIATORS OF CHANGE IN HUMAN HYPOTHALAMIC FUNCTION AND RELATED PHARMACEUTICAL COMPOSITIONS AND METHODS PHERIN CORPORATION (US) 1994-12-22 — — WO claimed
WO-1993020097-A1 17-SUBSTITUTED STEROIDS USEFUL IN CANCER TREATMENT BRITISH TECHNOLOGY GROUP LTD. (GB) 1993-10-14 — — WO claimed
US-4272445-A STEROIDS, BASIC CATALYSTS, ALKYLATION BEECHAM GROUP LIMITED (GB) 1981-06-09 — — US claimed
US-4118488-A 4-Androsten-3-ones and process for the preparation thereof SCHERING AKTIENGESELLSCHAFT (DE) 1978-10-03 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193095-A9 PHARMACEUTICAL COMPOSITIONS LIPA, LIPC, MGLL CYP19A1 674/4885SHBG 1170/4885HSD17B10 222/4885
US-20200237784-A1 PHARMACEUTICAL COMPOSITIONS LIPA, LIPC, MGLL CYP19A1 674/4885SHBG 1170/4885HSD17B10 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.